Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

AGO Score (DESKTOP)

The AGO (Arbeitsgemeinschaft Gynäkologische Onkologie) Score identifies patients with recurrent platinum-sensitive ovarian cancer who are likely to achieve complete resection (R0) at secondary cytoreductive surgery.

Evidence-based context for fast calculator use

Purpose:
AGO DESKTOP score predicts complete resection likelihood in recurrent ovarian cancer to guide secondary cytoreductive surgery decisions.
Population:
patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment
Factors:
ECOG Performance Status 0?, Ascites < 500 mL?, Complete Resectionat Primary Surgery?
Reference:
Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702-1710.
HomeAGO Score (DESKTOP)
Pin your most used calculators here by clicking the star in the dropdown.

AGO Score (DESKTOP)

Clinical Context & Background

The AGO (Arbeitsgemeinschaft Gynäkologische Onkologie) Score identifies patients with recurrent platinum-sensitive ovarian cancer who are likely to achieve complete resection (R0) at secondary cytoreductive surgery. It was developed from the DESKTOP trials.
Primary Source EvidenceHarter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702-1710.
Formula Logic
Positive if ALL 3 criteria are met.

Reference Data

AGO ScoreCriteria MetRecommendation
Positive3 of 3Consider Secondary Cytoreduction (High R0 rate)
Negative0 - 2Chemotherapy alone typically preferred

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use AGO Score (DESKTOP) when aGO DESKTOP score predicts complete resection likelihood in recurrent ovarian cancer to guide secondary cytoreductive surgery decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Positive through Negative.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm organ site, pathology, menopausal or postoperative context, imaging, biomarker assay, and specialist referral pathway.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Adnexal-mass, cervical postoperative, endometrial, and ovarian cytoreduction models answer different clinical questions.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment

How to apply this result

For a representative case, verify ECOG Performance Status 0?, Ascites < 500 mL?, Complete Resectionat Primary Surgery?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Gynecologic Oncology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

FIGO GTN Risk ScoreRMI (Risk of Malignancy Index)ROMA Score (Ovarian)

Frequently Asked Questions

When should AGO Score (DESKTOP) be used?

Use it for patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment when all required inputs and the intended clinical setting are confirmed.

Can AGO Score (DESKTOP) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.